Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy
The study will be conducted in two parts:
Dose determination of Irinotecan Liposome Injection
A randomized, efficacy study of Irinotecan Liposome Injection versus Topotecan
Principal Investigator
Co-Investigator(s)
Rajeswari Chellappah, M.D., Jasdeepa Nagi, M.D., Brian K. Kim, M.D, Kristin N. Arreola, M.D., Nitin Rohatgi, MD, Sivakumar Reddy, M.D., Vijay Suhag, M.D.
Funder
Ipsen Bioscience
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH